Beyond The Numbers: 4 Analysts Discuss Regenxbio Stock

4 analysts have expressed a variety of opinions on Regenxbio RGNX over the past quarter, offering a diverse set of opinions from bullish to bearish.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $31.5, along with a high estimate of $45.00 and a low estimate of $21.00. A 7.35% drop is evident in the current average compared to the previous average price target of $34.00.

Breaking Down Analyst Ratings: A Detailed Examination

In examining recent analyst actions, we gain insights into how financial experts perceive Regenxbio. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Regenxbio. This offers insight into analysts' perspectives on the current state of the company.
• Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Regenxbio compared to the broader market.
• Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Regenxbio's stock. This examination reveals shifts in analysts' expectations over time.

Capture valuable insights into Regenxbio's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on Regenxbio analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Discovering Regenxbio: A Closer Look

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Regenxbio: Delving into Financials

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Revenue Growth: Regenxbio's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately -29.13%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Regenxbio's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -283.12%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Regenxbio's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -18.64%, the company may face hurdles in achieving optimal financial returns.

Return on Assets (ROA): Regenxbio's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -10.41%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: Regenxbio's debt-to-equity ratio is below the industry average. With a ratio of 0.29, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

Understanding the Relevance of Analyst Ratings

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

This article was generated by Benzinga's automated content engine and reviewed by an editor.